Liu Wenjuan, Zuo Bingli, Liu Wenting, Huo Yanfei, Zhang Nasha, Yang Ming
Shandong Provincial Key Laboratory of Radiation Oncology, Cancer Research Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province 250117, China.
Human Resources Department, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong Province 250117, China.
Biochim Biophys Acta Rev Cancer. 2023 Nov;1878(6):188982. doi: 10.1016/j.bbcan.2023.188982. Epub 2023 Sep 19.
Lung cancer has the highest mortality and morbidity rates among all cancers worldwide. Despite many complex treatment options, including radiotherapy, chemotherapy, targeted drugs, immunotherapy, and combinations of these treatments, efficacy is low in cases of resistance to therapy, metastasis, and advanced disease, contributing to low overall survival. There is a pressing need for the discovery of novel biomarkers and therapeutic targets for the early diagnosis of lung cancer and to determine the efficacy and outcomes of drug treatments. There is now substantial evidence for the diagnostic and prognostic value of long noncoding RNAs (lncRNAs). This review briefly discusses recent findings on the roles and mechanisms of action of lncRNAs in the responses to therapy in non-small cell lung cancer.
在全球所有癌症中，肺癌的死亡率和发病率最高。尽管有许多复杂的治疗选择，包括放疗、化疗、靶向药物、免疫疗法以及这些治疗方法的联合使用，但在治疗耐药、转移和晚期疾病的情况下，疗效较低，导致总体生存率较低。迫切需要发现新的生物标志物和治疗靶点，用于肺癌的早期诊断，并确定药物治疗的疗效和结果。目前有大量证据表明长链非编码RNA（lncRNA）具有诊断和预后价值。本综述简要讨论了lncRNA在非小细胞肺癌治疗反应中的作用和作用机制的最新研究结果。
